Market Overview

UPDATE: JP Morgan Upgrades Teva Pharmaceuticals

Share:
Related TEVA
10 Notable Stocks Trading Ex-Dividend Thursday, December 1
Jim Cramer Shares His Opinion On Teva, Visa, New York Mortgage Trust And Empire State Realty Trust
S&P 500 Weekly Update: A Welcome Pause In This Long Term Uptrend (Seeking Alpha)

On Friday, JP Morgan upgraded shares of Teva Pharmaceuticals (NYSE: TEVA) from Underweight to Neutral and raised the profit target to $49.

Analyst Chris Schott is encouraged by “favorable initial Copaxone 3x weekly trends and the potential for additional cost cutting activity,” but remains “less enthusiastic around Teva's organic growth prospects and its P&L reliance on Copaxone.”

Schott expects Teva management's “willingness to consider larger business development opportunities will be well received.”

Shares of Teva are up 21 percent year-to-date and up 1.8 percent to $48.82 during Friday's session.

Latest Ratings for TEVA

DateFirmActionFromTo
Nov 2016JefferiesDowngradesBuyHold
Nov 2016Morgan StanleyDowngradesOverweightEqual-Weight
Nov 2016BTIG ResearchDowngradesBuyNeutral

View More Analyst Ratings for TEVA
View the Latest Analyst Ratings

Posted-In: Chris Schott JP MorganAnalyst Color Analyst Ratings

 

Related Articles (TEVA)

View Comments and Join the Discussion!